in general, bio manufacturers face challenges in the fill/finish step when dealing with biologics. Particularly the management of time when vaccines are out of controlled storage. Hence, IDT being close to CSL is another leading advantage moving forward.
fill/finish operations are predominantly outsourced to create additional capacity and expediate expansions and effective management. it is critical to the scale up of manufacturing.
IDT media thread, page-149
Add IDT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $53.69M | |||
| Open | High | Low | Value | Volume |
| 12.5¢ | 12.5¢ | 12.5¢ | $18.90K | 151.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 498714 | 12.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.0¢ | 157806 | 2 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| IDT (ASX) Chart |